Akili

Akili Interactive Labs raises $160M in equity and debt to transform cognitive healthcare via prescription videogame treatments

by

Akili rais­es $110m to build its dig­i­tal ther­a­peu­tics pipeline (phar­mafo­rum):

Endeav­or­Rx became the first and so far only approved pre­scrip­tion video game treat­ment in the US when it was cleared by the FDA last year to treat atten­tion-deficit hyper­ac­tiv­i­ty dis­or­der (ADHD), and has also been giv­en a green light in Europe. [Read more…] about Akili Inter­ac­tive Labs rais­es $160M in equi­ty and debt to trans­form cog­ni­tive health­care via pre­scrip­tion videogame treatments

Latest brain research, tools and teasers to think outside the mental health status quo box

by

__

Time for a new edi­tion of Sharp­Brains’ e‑newsletter, fea­tur­ing a range of  research find­ings, resources, brain teasers and rid­dles to help trans­late emerg­ing neu­ro­science into real-world appli­ca­tions and improve our col­lec­tive brain & men­tal health.

New thinking:

New research:

New tools:

Fun brain teasers:

 

Have a great month of March,

 

The Sharp­Brains Team

Large study finds positive yet mixed results from Akili’s digital therapeutic for kids with ADHD

by

__

Full pub­li­ca­tion of piv­otal tri­al data out­lines Akil­i’s case for FDA reg­u­la­tion (Mobi­Health­News):

“A full tran­script of STARS-ADHD — the piv­otal tri­al of Akili Interactive’s video game-like pedi­atric atten­tion deficit treat­ment — has been pub­lished in The Lancet Dig­i­tal Health jour­nal, pro­vid­ing onlook­ers a clear view of data fuel­ing the dig­i­tal ther­a­peu­tic company’s pend­ing FDA sub­mis­sion [Read more…] about Large study finds pos­i­tive yet mixed results from Akili’s dig­i­tal ther­a­peu­tic for kids with ADHD

Lifestyle and neurotechnology over genetics

by

”

Dear col­league,

It’s remark­able how quick­ly things are chang­ing, final­ly, in brain health and men­tal health — see for exam­ple what’s new with Inter­ax­on, Akili, Neu­raMetrix, Apple, Calm, Halo Neu­ro­science, Mind­strong Health, Novar­tis, Pear Ther­a­peu­tics, and life­long neu­ro­ge­n­e­sis, all in the last 6 months!

Please enjoy the May edi­tion of Sharp­Brains eNewslet­ter below, and con­sid­er join­ing the Sharp­Brains Vir­tu­al Sum­mit this Decem­ber to dis­cuss the lat­est and help shape the next 🙂

New research:

New tools:

New thinking:

 

Have a great month of June,

 

The Sharp­Brains Team

Reinventing Brain Medicine, Pharma adopts Digital Therapeutics: Evidence-based videogames, smartphone apps, and sensors

by

___

From app store to drug store, dig­i­tal health is redefin­ing pharma’s pipeline (STAT):

“The pitch­es always sound­ed promis­ing: A new soft­ware app could track glu­cose lev­els for peo­ple with dia­betes or soothe the brains of insom­ni­acs. Most phar­ma exec­u­tives would polite­ly smile and nod, but then park their mon­ey some­where else.

Not any­more. [Read more…] about Rein­vent­ing Brain Med­i­cine, Phar­ma adopts Dig­i­tal Ther­a­peu­tics: Evi­dence-based videogames, smart­phone apps, and sensors

Update: Why monitoring Typing Cadence may help detect early Parkinson’s and Alzheimer’s Disease

by

Above: Pat­tern of Typ­ing Cadence in 52-year-old male with Parkin­son’s. Source: NeuraMetrix

_____

Time for Sharp­Brains’ first eNewslet­ter in 2018, offer­ing a fas­ci­nat­ing sneek peek into the rapid­ly grow­ing toolk­it to mea­sure and improve brain health. 

(And don’t miss the fun teas­er at the end!)

New thinking:

New research:

New tools:

 

 

Final­ly, a quick brain teas­er. What do you see first, ani­mals or people?

 

Have a great month of February!